This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page introduces a 2022 phase 2 trial comparing a single psilocybin session under psychological support in 233 adults experiencing a major depressive episode that had not responded adequately to multiple treatments. Participants were randomized to 3 different conditions, and the primary assessment was change in a depression-rating scale at 3 weeks.
The study used standardized synthetic psilocybin, not mushrooms containing psilocybin. It included preparation, monitoring by specialists, and post-session support. It did not test the effects of the substance alone or safety in unsupervised settings.
Study design
Participants were assigned to high, medium, or functionally low-dose control groups and underwent a single session. Raters were blinded, and the primary outcome was the change in the Montgomery–Åsberg Depression Rating Scale from baseline to week 3. Response and remission, persistence, daily functioning, and adverse events were also followed.
Because subjective effects differed substantially among conditions, participants and support staff were likely able to infer allocation. The low-dose condition was not a fully inactive placebo, yet it could not erase the experiential difference from the high-dose condition.
Content
Treatment-resistant depression includes the selection criterion of inadequate response to existing treatments. Severity, prior treatments, and comorbidities differ from the broader population with depression. Medication adjustments and support during research participation may also influence outcomes.
The principal time point was week 3, capturing early change but not establishing relapse prevention or long-term functioning. Suicidal ideation and behavior, self-harm, adverse events, and their temporal relationships need to be examined alongside efficacy.
Results
The high-dose group showed a greater mean improvement on the depression-rating scale at week 3 than the low-dose group. The difference between the medium- and low-dose groups was not equally clear. Some participants met response and remission criteria, while others did not improve or later experienced stronger symptoms again.
Some form of adverse event was reported in 179 of 233 participants. Alongside headache, nausea, and dizziness, events involving suicidal ideation, suicidal behavior, and self-harm were recorded across groups, requiring careful safety follow-up. The trial shows an efficacy signal, but it was not a phase 3 trial establishing the full balance of benefits and harms.
Limitations
Functional unblinding from subjective effects, a short primary follow-up, selected participants, and support at specialist sites limit generalization. Interpretation of the low-dose control, multiple outcomes, missing data, and expectancy effects also require consideration.
Industry funding and researcher relationships should be checked in the original disclosure. The sample size and follow-up were insufficient to assess rare adverse events or long-term relapse.
Even with multiple countries and sites, the population met trial eligibility criteria and had access to specialist support. Whether the same support resources can be reproduced in routine care is a separate implementation question.
Safety
Treatment-resistant depression itself carries background symptom fluctuation and suicide risk. Not every post-session event can be established as caused by the drug, but uncertainty about causation is not grounds to ignore it. Continued assessment, crisis response, and support systems were part of the research conditions.
This page does not guide self-administration or medication discontinuation. Ordinary specialist care and emergency support take priority when acute psychological distress, manic or psychotic symptoms, or suicidal ideation are present.
Source and rights
Original source: Goodwin GM, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. The New England Journal of Medicine. 2022;387:1637–1648. DOI: 10.1056/NEJMoa2206443.
Respecting the publisher’s copyright, this page is a detailed introduction that independently summarizes the study design, results, safety, and limitations based on public bibliographic information and the abstract. It is not a full translation or republication of figures and tables.